Meeting
2012 ASCO Annual Meeting
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen.
Authors
Waleed Badreldin
St Bartholomew's Hospital, London, United Kingdom
Waleed Badreldin , Simon Chowdhury , Stephen John Harland , Danish Mazhar , Thomas Powles , Peter Wilson , Jonathan Shamash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4529)
DOI
10.1200/jco.2012.30.15_suppl.4529
Abstract #
4529
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa
Poster
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2017 Gastrointestinal Cancers Symposium
Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer.
First Author: Mark Ricigliano
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers.
First Author: Rudolph M. Navari